MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients

M. I. Alvarez-Mora, L. Rodriguez-Revenga, I. Madrigal, F. Torres-Silva, E. Mateu-Huertas, E. Lizano, M. R. Friedländer, E. Martí, Xavier P. Estivill, M. Milà

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with FMR1 gene premutation alleles (55-200 CGG repeats). Fragile X-associated tremor/ataxia syndrome clinical core features include action tremor, gait ataxia, cognitive deficits progressing to dementia, and frequently parkinsonism. Although the pathogenic molecular mechanism of FXTAS is not completely understood, the restriction of the phenotype to the FMR1 premutation range has given rise to a model based on a RNA toxic gain-of-function. Since the identification of the first microRNAs (miRNAs) and their role in normal development, several studies have associated them with neurodegenerative diseases such as Parkinson, Alzheimer and Huntington diseases, suggesting that they play a key role in brain development, as well as in its morphogenesis. Herein, we present the characterization of miRNA expression profiles in FXTAS male patients using deep sequencing-based technologies and microarray technology. Deep sequencing analysis evidenced 83 miRNAs that were significantly deregulated whereas microarray analysis showed 31. When comparing these results, 14 miRNAs were found deregulated in FXTAS patients. MiR-424 and miR-574-3p showed significant fold change adjusted P-values in both platforms in FXTAS patients. MiR-424 has been founded substantially and specifically enriched in human cerebral cortical white matter of Alzheimer disease patients, which, together with cerebral atrophy, is a prominent imaging finding in individuals with FXTAS. The study provides the first systematic evidence of differential miRNA expression changes in FXTAS blood samples. Although further studies are necessary to better characterize the miRNA function in FXTAS disorder, our results suggest that they might contribute to its pathogenesis.

Original languageEnglish
Pages (from-to)595-603
Number of pages9
JournalGenes, Brain and Behavior
Volume12
Issue number6
DOIs
Publication statusPublished - Aug 2013
Externally publishedYes

Fingerprint

MicroRNAs
High-Throughput Nucleotide Sequencing
Neurodegenerative Diseases
Alzheimer Disease
Gait Ataxia
Technology
Leukoencephalopathies
Fragile X Tremor Ataxia Syndrome
Poisons
Huntington Disease
Parkinsonian Disorders
Tremor
Microarray Analysis
Morphogenesis
Atrophy
Parkinson Disease
Dementia
Alleles
RNA
Phenotype

Keywords

  • Expression profile
  • FMR1 gene
  • FXTAS
  • High-throughput technologies
  • IsomiR
  • miRNAs
  • Mitochondrial dysfunction
  • Neurodegeneration
  • Oxidative stress
  • Trimming variants

ASJC Scopus subject areas

  • Genetics
  • Neurology
  • Behavioral Neuroscience

Cite this

Alvarez-Mora, M. I., Rodriguez-Revenga, L., Madrigal, I., Torres-Silva, F., Mateu-Huertas, E., Lizano, E., ... Milà, M. (2013). MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. Genes, Brain and Behavior, 12(6), 595-603. https://doi.org/10.1111/gbb.12061

MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. / Alvarez-Mora, M. I.; Rodriguez-Revenga, L.; Madrigal, I.; Torres-Silva, F.; Mateu-Huertas, E.; Lizano, E.; Friedländer, M. R.; Martí, E.; Estivill, Xavier P.; Milà, M.

In: Genes, Brain and Behavior, Vol. 12, No. 6, 08.2013, p. 595-603.

Research output: Contribution to journalArticle

Alvarez-Mora, MI, Rodriguez-Revenga, L, Madrigal, I, Torres-Silva, F, Mateu-Huertas, E, Lizano, E, Friedländer, MR, Martí, E, Estivill, XP & Milà, M 2013, 'MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients', Genes, Brain and Behavior, vol. 12, no. 6, pp. 595-603. https://doi.org/10.1111/gbb.12061
Alvarez-Mora MI, Rodriguez-Revenga L, Madrigal I, Torres-Silva F, Mateu-Huertas E, Lizano E et al. MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. Genes, Brain and Behavior. 2013 Aug;12(6):595-603. https://doi.org/10.1111/gbb.12061
Alvarez-Mora, M. I. ; Rodriguez-Revenga, L. ; Madrigal, I. ; Torres-Silva, F. ; Mateu-Huertas, E. ; Lizano, E. ; Friedländer, M. R. ; Martí, E. ; Estivill, Xavier P. ; Milà, M. / MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients. In: Genes, Brain and Behavior. 2013 ; Vol. 12, No. 6. pp. 595-603.
@article{bd208a6b119b4a978fed448891954c41,
title = "MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients",
abstract = "Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with FMR1 gene premutation alleles (55-200 CGG repeats). Fragile X-associated tremor/ataxia syndrome clinical core features include action tremor, gait ataxia, cognitive deficits progressing to dementia, and frequently parkinsonism. Although the pathogenic molecular mechanism of FXTAS is not completely understood, the restriction of the phenotype to the FMR1 premutation range has given rise to a model based on a RNA toxic gain-of-function. Since the identification of the first microRNAs (miRNAs) and their role in normal development, several studies have associated them with neurodegenerative diseases such as Parkinson, Alzheimer and Huntington diseases, suggesting that they play a key role in brain development, as well as in its morphogenesis. Herein, we present the characterization of miRNA expression profiles in FXTAS male patients using deep sequencing-based technologies and microarray technology. Deep sequencing analysis evidenced 83 miRNAs that were significantly deregulated whereas microarray analysis showed 31. When comparing these results, 14 miRNAs were found deregulated in FXTAS patients. MiR-424 and miR-574-3p showed significant fold change adjusted P-values in both platforms in FXTAS patients. MiR-424 has been founded substantially and specifically enriched in human cerebral cortical white matter of Alzheimer disease patients, which, together with cerebral atrophy, is a prominent imaging finding in individuals with FXTAS. The study provides the first systematic evidence of differential miRNA expression changes in FXTAS blood samples. Although further studies are necessary to better characterize the miRNA function in FXTAS disorder, our results suggest that they might contribute to its pathogenesis.",
keywords = "Expression profile, FMR1 gene, FXTAS, High-throughput technologies, IsomiR, miRNAs, Mitochondrial dysfunction, Neurodegeneration, Oxidative stress, Trimming variants",
author = "Alvarez-Mora, {M. I.} and L. Rodriguez-Revenga and I. Madrigal and F. Torres-Silva and E. Mateu-Huertas and E. Lizano and Friedl{\"a}nder, {M. R.} and E. Mart{\'i} and Estivill, {Xavier P.} and M. Mil{\`a}",
year = "2013",
month = "8",
doi = "10.1111/gbb.12061",
language = "English",
volume = "12",
pages = "595--603",
journal = "Genes, Brain and Behavior",
issn = "1601-1848",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - MicroRNA expression profiling in blood from fragile X-associated tremor/ataxia syndrome patients

AU - Alvarez-Mora, M. I.

AU - Rodriguez-Revenga, L.

AU - Madrigal, I.

AU - Torres-Silva, F.

AU - Mateu-Huertas, E.

AU - Lizano, E.

AU - Friedländer, M. R.

AU - Martí, E.

AU - Estivill, Xavier P.

AU - Milà, M.

PY - 2013/8

Y1 - 2013/8

N2 - Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with FMR1 gene premutation alleles (55-200 CGG repeats). Fragile X-associated tremor/ataxia syndrome clinical core features include action tremor, gait ataxia, cognitive deficits progressing to dementia, and frequently parkinsonism. Although the pathogenic molecular mechanism of FXTAS is not completely understood, the restriction of the phenotype to the FMR1 premutation range has given rise to a model based on a RNA toxic gain-of-function. Since the identification of the first microRNAs (miRNAs) and their role in normal development, several studies have associated them with neurodegenerative diseases such as Parkinson, Alzheimer and Huntington diseases, suggesting that they play a key role in brain development, as well as in its morphogenesis. Herein, we present the characterization of miRNA expression profiles in FXTAS male patients using deep sequencing-based technologies and microarray technology. Deep sequencing analysis evidenced 83 miRNAs that were significantly deregulated whereas microarray analysis showed 31. When comparing these results, 14 miRNAs were found deregulated in FXTAS patients. MiR-424 and miR-574-3p showed significant fold change adjusted P-values in both platforms in FXTAS patients. MiR-424 has been founded substantially and specifically enriched in human cerebral cortical white matter of Alzheimer disease patients, which, together with cerebral atrophy, is a prominent imaging finding in individuals with FXTAS. The study provides the first systematic evidence of differential miRNA expression changes in FXTAS blood samples. Although further studies are necessary to better characterize the miRNA function in FXTAS disorder, our results suggest that they might contribute to its pathogenesis.

AB - Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder associated with FMR1 gene premutation alleles (55-200 CGG repeats). Fragile X-associated tremor/ataxia syndrome clinical core features include action tremor, gait ataxia, cognitive deficits progressing to dementia, and frequently parkinsonism. Although the pathogenic molecular mechanism of FXTAS is not completely understood, the restriction of the phenotype to the FMR1 premutation range has given rise to a model based on a RNA toxic gain-of-function. Since the identification of the first microRNAs (miRNAs) and their role in normal development, several studies have associated them with neurodegenerative diseases such as Parkinson, Alzheimer and Huntington diseases, suggesting that they play a key role in brain development, as well as in its morphogenesis. Herein, we present the characterization of miRNA expression profiles in FXTAS male patients using deep sequencing-based technologies and microarray technology. Deep sequencing analysis evidenced 83 miRNAs that were significantly deregulated whereas microarray analysis showed 31. When comparing these results, 14 miRNAs were found deregulated in FXTAS patients. MiR-424 and miR-574-3p showed significant fold change adjusted P-values in both platforms in FXTAS patients. MiR-424 has been founded substantially and specifically enriched in human cerebral cortical white matter of Alzheimer disease patients, which, together with cerebral atrophy, is a prominent imaging finding in individuals with FXTAS. The study provides the first systematic evidence of differential miRNA expression changes in FXTAS blood samples. Although further studies are necessary to better characterize the miRNA function in FXTAS disorder, our results suggest that they might contribute to its pathogenesis.

KW - Expression profile

KW - FMR1 gene

KW - FXTAS

KW - High-throughput technologies

KW - IsomiR

KW - miRNAs

KW - Mitochondrial dysfunction

KW - Neurodegeneration

KW - Oxidative stress

KW - Trimming variants

UR - http://www.scopus.com/inward/record.url?scp=84881110854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881110854&partnerID=8YFLogxK

U2 - 10.1111/gbb.12061

DO - 10.1111/gbb.12061

M3 - Article

VL - 12

SP - 595

EP - 603

JO - Genes, Brain and Behavior

JF - Genes, Brain and Behavior

SN - 1601-1848

IS - 6

ER -